Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

<p>Cell line and PDX genetics</p>

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Elizabeth R. Tucker (15053624) (author)
Weitere Verfasser:	Irene Jiménez (15053627) (author), Lindi Chen (15053630) (author), Angela Bellini (15053633) (author), Chiara Gorrini (15053636) (author), Elizabeth Calton (15053639) (author), Qiong Gao (15053642) (author), Harvey Che (15053645) (author), Evon Poon (15053648) (author), Yann Jamin (14936271) (author), Barbara Martins Da Costa (15053651) (author), Karen Barker (15053654) (author), Sumana Shrestha (15053657) (author), J. Ciaran Hutchinson (15053660) (author), Simran Dhariwal (15053663) (author), Angharad Goodman (15053666) (author), Elaine Del Nery (15053669) (author), Pierre Gestraud (15022362) (author), Jaydutt Bhalshankar (15053672) (author), Yasmine Iddir (15053675) (author), Elnaz Saberi-Ansari (15053678) (author), Alexandra Saint-Charles (15053681) (author), Birgit Geoerger (14952291) (author), Maria Eugénia Marques Da Costa (15053684) (author), Cécile Pierre-Eugène (15053687) (author), Isabelle Janoueix-Lerosey (15053690) (author), Didier Decaudin (15053693) (author), Fariba Nemati (15053696) (author), Angel M. Carcaboso (15053699) (author), Didier Surdez (14941221) (author), Olivier Delattre (15053702) (author), Sally L. George (15053705) (author), Louis Chesler (14934315) (author), Deborah A. Tweddle (15053708) (author), Gudrun Schleiermacher (15053711) (author)
Veröffentlicht:	2025
Schlagworte:	Cancer Therapeutic Research and Development Methods and Technology Chemotherapy Combination chemotherapy Pediatric Cancers Preclinical Models Animal models of cancer In vitro models of cancer Xenograft models Small Molecule Agents Kinase inhibitors Translational Research
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
von: Elizabeth R. Tucker (15053624)
Veröffentlicht: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
von: Elizabeth R. Tucker (15053624)
Veröffentlicht: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
von: Elizabeth R. Tucker (15053624)
Veröffentlicht: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
von: Elizabeth R. Tucker (15053624)
Veröffentlicht: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
von: Elizabeth R. Tucker (15053624)
Veröffentlicht: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
von: Alyssa C. Flint (16676029)
Veröffentlicht: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
von: Alyssa C. Flint (16676029)
Veröffentlicht: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
von: Anne-Florence Blandin (15056366)
Veröffentlicht: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
von: Anne-Florence Blandin (15056366)
Veröffentlicht: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
von: Anne-Florence Blandin (15056366)
Veröffentlicht: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
von: Anne-Florence Blandin (15056366)
Veröffentlicht: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
von: Anne-Florence Blandin (15056366)
Veröffentlicht: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
von: Anne-Florence Blandin (15056366)
Veröffentlicht: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
von: Anne-Florence Blandin (15056366)
Veröffentlicht: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
von: Arun Kanakkanthara (14937731)
Veröffentlicht: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
von: Arun Kanakkanthara (14937731)
Veröffentlicht: (2025)

Supplementary Table S1 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
von: Ke Peng (15048177)
Veröffentlicht: (2025)

Supplementary Table S2 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
von: Ke Peng (15048177)
Veröffentlicht: (2025)

Supplementary Table S3 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
von: Ke Peng (15048177)
Veröffentlicht: (2025)

Supplementary Table S4 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
von: Ke Peng (15048177)
Veröffentlicht: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
von: Katie E. Hebron (15046889)
Veröffentlicht: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
von: Katie E. Hebron (15046889)
Veröffentlicht: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
von: Katie E. Hebron (15046889)
Veröffentlicht: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
von: Katie E. Hebron (15046889)
Veröffentlicht: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
von: Katie E. Hebron (15046889)
Veröffentlicht: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
von: Katie E. Hebron (15046889)
Veröffentlicht: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
von: Katie E. Hebron (15046889)
Veröffentlicht: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
von: Zev A. Wainberg (15047031)
Veröffentlicht: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
von: Sheheryar Kabraji (15050565)
Veröffentlicht: (2025)

Supplementary Movie S1 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
von: Jesse C. Patterson (14962862)
Veröffentlicht: (2025)

Supplementary Movie S2 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
von: Jesse C. Patterson (14962862)
Veröffentlicht: (2025)

Supplementary Movie S3 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
von: Jesse C. Patterson (14962862)
Veröffentlicht: (2025)

Supplementary Movie S4 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
von: Jesse C. Patterson (14962862)
Veröffentlicht: (2025)

Supplementary Movie S5 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
von: Jesse C. Patterson (14962862)
Veröffentlicht: (2025)

Supplementary Movie S6 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
von: Jesse C. Patterson (14962862)
Veröffentlicht: (2025)

Supplementary Movie S7 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
von: Jesse C. Patterson (14962862)
Veröffentlicht: (2025)

Supplementary Movie S8 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
von: Jesse C. Patterson (14962862)
Veröffentlicht: (2025)

Supplementary Movie S9 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
von: Jesse C. Patterson (14962862)
Veröffentlicht: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
von: Caleb N. Seavey (15056489)
Veröffentlicht: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
von: Caleb N. Seavey (15056489)
Veröffentlicht: (2025)

Cannot write session to /tmp/vufind_sessions/sess_upphdct1egulthdvu0d170r43q